| Fidaxomicin is a non-absorbed macrocyclic antibiotic, and is the first antimicrobial to be approved by the FDA for the treatment of Clostridium difficile infection (CDI) in 20 years. Fidaxomicin works by inhibiting sporulation by CDI, sustaining clinical response and reducing recurrences of this pathogen. Synonyms: 3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-[[[6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-beta-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-beta-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-oxacyclooctadeca-3,5,9,13,15-pentaen-2-one, Clostomicin B1, Dificid, Dificlir, Fidaxomicin, Fidaxomycin, Lipiarmicin, Lipiarmycin, Lipiarmycin A 3, OPT 80, PAR 01, PAR 101, R-Tiacumicin B, Tiacumicin CAS Number: 873857-62-6 Molecular Formula: C52H74Cl2O18 Molecular Weight: 1058.04 Appearance: White to off-white powder Purity: 98% (HPLC) Melting Point: >160C Solubility: DMSO (Slightly), Methanol (Slightly)x Storage and Stability: Store at 4C under inert atmosphere. For maximum recovery of product, centrifuge the original vial prior to removing the cap. |
